Zacks Investment Research upgraded shares of LONZA GRP AG/ADR (OTCMKTS:LZAGY) from a hold rating to a buy rating in a research report report published on Saturday morning, Zacks.com reports. Zacks Investment Research currently has $59.00 price objective on the stock.
According to Zacks, “Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company’s Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland. “
A number of other research analysts have also weighed in on the stock. ValuEngine raised shares of LONZA GRP AG/ADR from a sell rating to a hold rating in a research note on Tuesday, March 17th. UBS Group lowered shares of LONZA GRP AG/ADR from a buy rating to a neutral rating in a research note on Thursday, May 14th. Finally, Morgan Stanley reissued an overweight rating on shares of LONZA GRP AG/ADR in a research note on Wednesday, June 24th.
LONZA GRP AG/ADR Company Profile
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. Its products and services cover bio research solutions, such as stem cells primary cells and media, cell culture, transfection, exosomes, and assay solutions; electrophoresis of nucleic acids and proteins; primary and stem cell protocols; Hepatocytes/ADMETox solutions for microsomes and primary cell culture applications; and CytoSMART system, a live cell imaging and monitoring system.
Further Reading: What is the return on assets (ROA) ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LONZA GRP AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LONZA GRP AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.